YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Baird Equity Asset Management recently released its "Small/Mid Cap Growth Strategy" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp rebound in the broader equity market duri…
Liquidia Corporation LQDA and Alkermes plc ALKS are both commercial-stage biopharmaceutical companies with specialty therapies and a similar mid-cap biotech investor profile. LQDA is focused on developing and commercializing therapies for…
Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult AD…
In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult A…
Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's conf PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Alkermes ALKS announced positive top-line data from a phase I proof-of-concept study evaluating its novel, investigational orexin 2 receptor (OX2R) agonist, ALKS 7290, for the treatment of attention-deficit hyperactivity disorder (ADHD). T…
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD. Continue Reading
[ADHD, attention deficit hyperactivity disorder, mental health, colorful hands of child, brain with cognitive difficulty] BeritK/iStock via Getty Images * Alkermes (ALKS [https://seekingalpha.com/symbol/ALKS]) is up ~7% in premarket tradin…
— ALKS 7290 is the First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful Improvements in ADHD Symptoms in Adults — — ALKS 7290 Was Generally Well Tolerated at All Doses Tested in Healthy Volunteers and Adults With ADHD — — P…
DUBLIN, September 16, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharma…
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder — — Stage One Submissi…
Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction valu…
It has been about a month since the last earnings report for Alkermes (ALKS). Shares have added about 1.7% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading…
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Rela…
Indivior Pharmaceuticals INDV agreed in August to combine with Supernus Pharmaceuticals SUPN in an all-stock merger of equals. The deal would shift Indivior from a business centered on opioid use disorder into a broader central nervous sys…
Indivior Pharmaceuticals INDV enters the second half of 2026 with accelerating Sublocade demand, a lower cost base and higher earnings guidance. The company is translating commercial momentum into stronger profitability and cash generation…
If you're interested in broad exposure to the Small Cap Blend segment of the US equity market, look no further than the Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC), a passively managed exchange traded fund launched on June 28…
Shares of Alkermes ALKS have risen 26.5% in the past three months, driven by strong sales growth across its proprietary product portfolio and continued progress in its clinical pipeline. Alkermes' proprietary products include Vivitrol for…
It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes stock has delivered a strong 84.5% return over the past ye…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes (NasdaqGS:ALKS) shares were in focus after the company rep…
Alkermes' (ALKS) base business supported the company's Q2 beat, while its orexin pipeline serves as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Alkermes plc Q2 2026 Earnings Call Summary - Moby Strategic Evolution and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Ta…
This article first appeared on GuruFocus. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alkermes PLC (NASDAQ:ALKS) reported a 34% year-over-…
Alkermes plc ALKS reported break-even earnings for the second quarter of 2026 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company had recorded earnings of 52 cents per share in the year-ago quarter. During the…
For the quarter ended June 2026, Alkermes (ALKS) reported revenue of $496.01 million, up 27% over the same period last year. EPS came in at $0, compared to $0.52 in the year-ago quarter. The reported revenue compares to the Zacks Consensus…
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items. This quar…
DUBLIN, July 28, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the co…
Major earnings expected before the bell on Tuesday include: * PayPal Holdings (PYPL [https://seekingalpha.com/symbol/PYPL]) * The Coca-Cola Company (KO [https://seekingalpha.com/symbol/KO]) * The Boeing Company (BA [https://seekingalpha.co…
Key Points Vanguard S&P 500 Growth ETF offers exposure to large-cap giants with a significantly lower expense ratio than the small-cap focused State Street fund State Street SPDR S&P 600 Small Cap Growth ETF is more diversified across sect…
The choice between Vanguard S&P 500 Growth ETF (NYSEMKT:VOOG) and State Street SPDR S&P 600 Small Cap Growth ETF (NYSEMKT:SLYG) hinges on whether an investor prefers large-cap stability and tech dominance or the potential higher volatility…
In recent trading, shares of Alkermes plc (Symbol: ALKS) have crossed above the average analyst 12-month target price of $52.83, changing hands for $52.97/share. When a stock reaches the target an analyst has set, the analyst logically has…
The market expects Adaptive Biotechnologies (ADPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing t…
Wall Street expects a year-over-year decline in earnings on higher revenues when Alkermes (ALKS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings pict…
Axsome Therapeutics AXSM announced that the FDA has accepted the company's new drug application (NDA) seeking approval for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. With the FDA accepting the NDA for review, a decis…
DUBLIN, July 14, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results. T…